These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30261668)

  • 1. Galectins in Cancer and Translational Medicine: From Bench to Bedside.
    Bartolazzi A
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261668
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor galectinology: insights into the complex network of a family of endogenous lectins.
    Lahm H; André S; Hoeflich A; Kaltner H; Siebert HC; Sordat B; von der Lieth CW; Wolf E; Gabius HJ
    Glycoconj J; 2004; 20(4):227-38. PubMed ID: 15115907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of galectins in high-fatality cancers.
    Dubé-Delarosbil C; St-Pierre Y
    Cell Mol Life Sci; 2018 Apr; 75(7):1215-1226. PubMed ID: 29119229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dawning of Translational Breast Cancer: From Bench to Bedside.
    Chen X; Fan S; Song E
    Adv Exp Med Biol; 2017; 1026():1-25. PubMed ID: 29282677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer.
    Punt S; Thijssen VL; Vrolijk J; de Kroon CD; Gorter A; Jordanova ES
    PLoS One; 2015; 10(6):e0129119. PubMed ID: 26066796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.
    van der Meel R; Gallagher WM; Oliveira S; O'Connor AE; Schiffelers RM; Byrne AT
    Drug Discov Today; 2010 Feb; 15(3-4):102-14. PubMed ID: 20035896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zebrafish in oncology.
    Barriuso J; Nagaraju R; Hurlstone A
    Aging (Albany NY); 2015 May; 7(5):286-7. PubMed ID: 26022157
    [No Abstract]   [Full Text] [Related]  

  • 8. Translational oncology toward benefiting cancer patients: the Sun Yat-sen University Cancer Center experience.
    Guerin M; Qian C; Zhong Q; Cui Q; Guo Y; Bei J; Shao J; Zhu X; Huang W; Wu J; Liu R; Liu Q; Wang J; Jia W; Zheng X; Zeng Y
    Sci China Life Sci; 2016 Oct; 59(10):1057-1062. PubMed ID: 23132500
    [No Abstract]   [Full Text] [Related]  

  • 9. Applying Genomics and Proteomics in Translational Surgical Oncology Research.
    Gemoll T; Meyer R; Habermann JK
    Eur Surg Res; 2015; 55(3):184-97. PubMed ID: 26339997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Biomarkers in the Era of Personalized Cancer Medicine.
    Ricciuti B; Leonardi GC; Brambilla M
    Dis Markers; 2019; 2019():5907238. PubMed ID: 31485277
    [No Abstract]   [Full Text] [Related]  

  • 11. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 12. Precision oncology: an overview.
    Garraway LA; Verweij J; Ballman KV
    J Clin Oncol; 2013 May; 31(15):1803-5. PubMed ID: 23589545
    [No Abstract]   [Full Text] [Related]  

  • 13. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research.
    Meropol NJ; Kris MG; Winer EP
    J Clin Oncol; 2012 Mar; 30(7):690-1. PubMed ID: 22215747
    [No Abstract]   [Full Text] [Related]  

  • 14. IT infrastructure components to support clinical care and translational research projects in a comprehensive cancer center.
    Prokosch HU; Ries M; Beyer A; Schwenk M; Seggewies C; Köpcke F; Mate S; Martin M; Bärthlein B; Beckmann MW; Stürzl M; Croner R; Wullich B; Ganslandt T; Bürkle T
    Stud Health Technol Inform; 2011; 169():892-6. PubMed ID: 21893875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bench to bedside: does preclinical practice in translational oncology need some rebuilding?
    Bertotti A; Trusolino L
    J Natl Cancer Inst; 2013 Oct; 105(19):1426-7. PubMed ID: 24052623
    [No Abstract]   [Full Text] [Related]  

  • 16. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 17. A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.
    Haas GP; Scher HI
    Urol Oncol; 2015 Mar; 33(3):115. PubMed ID: 25620153
    [No Abstract]   [Full Text] [Related]  

  • 18. A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.
    Haas GP; Scher HI
    Urol Oncol; 2015 Jun; 33(6):269. PubMed ID: 25817318
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging trends in biomarker discovery: Ease of prognosis and prediction in cancer.
    Sharma AK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):iii-iv. PubMed ID: 29857038
    [No Abstract]   [Full Text] [Related]  

  • 20. Translational research in oral cancer: "A challenging key step in moving from bench to bedside".
    Sharma N; Annigeri RG
    J Cancer Res Ther; 2018; 14(2):245-248. PubMed ID: 29516902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.